Upstream Bio Rings the Nasdaq Stock Market Opening Bell

Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, visits the Nasdaq MarketSite in Times Square to celebrate its recent initial public offering. The Company is developing verekitug, the only known antagonist currently in development that targets the receptor for the thymic stromal lymphopoietin (TSLP) for the treatment of inflammatory diseases.

In honor of the occasion, Rand Sutherland, M.D., M.P.H., Chief Executive Officer, rings the Opening Bell.